AUG 10, 2016 10:23 AM PDT

Hopkins Doctors Challenge Routine Testing for Breast Cancer

WRITTEN BY: Xuan Pham
When it comes to some cancer types, more testing may not always pay off. It may, in fact, waste millions of dollars that could go towards other healthcare burdens. That’s what Johns Hopkins doctors report, after finding that for a common type of noninvasive breast cancer, routine testing at the onset of diagnosis may be redundant and highly wasteful. How wasteful? The scientists estimated at least $35 million could be saved annually if this initial testing was not made so routine.

Every year, an estimated 60,000 patients in the US are diagnosed with a noninvasive breast cancer type known as ductal carcinoma in situ (DCIS). This condition is marked by presence of cancer cells in the milk ducts or lobules, which have not spread to anywhere else.

According to Hopkins researchers, it’s become almost a reflex for doctors nationwide to order core needle biopsies for hormone receptor testing following a DCIS finding. The routine procedure determines whether the cancer is noninvasive or invasive, and tests for the presence of estrogen and progesterone receptors.

But, regardless of the outcome of the biopsy, doctors end up making the same recommendation: lumpectomy or mastectomy to remove the cancerous tissues. This is the first line of argument against the needle biopsy.

Furthermore, the first round of testing shows itself to be essentially redudant later on. Pedram Argani, senior lead of the study said, “Almost 20 percent of the time, the excision reveals that the noninvasive DCIS that the core needle biopsy caught is actually accompanied by invasive breast cancer. So you have to receptor-test the invasive cancer that the core biopsy missed. That means the testing of the core biopsy with DCIS was useless."
 

But perhaps the most compelling argument to drop the initial needle biopsy may be its demonstrated lack of efficacy on patient survival. The premise behind this treatment is to catch hormone receptor-positive DCIS types, for which tamoxifen can be taken to inhibit the receptors and prevent cancer recurrence. However, the effect of this treatment overall is modest at best, while the side effects can be severe.

"Two-thirds of our DCIS study patients did not receive hormone therapy," said Argani, "even after excision confirmed their hormone-receptor positive DCIS status. So analyzing their needle biopsies or surgical excisions for receptors would have clearly been unnecessary for them."

What it amounts to, in the researchers’ perspective, is an expensive medical bill that’s not necessary. Every early receptor test costs about $140 per patient. "Extrapolating that to the roughly 60,000 U.S. patients diagnosed with DCIS yearly puts the cost at about $8.5 million," added Argani. "The unnecessary cost of automatically testing DCIS in excisions when the information is not used is $26.5 million, which adds up to $35 million dollars per year in the U.S."

So persuasive are the results that the Johns Hopkins Hospital have already abandoned this practice at the start of the year, 8 months before the formal publication of the study. Perhaps other hospitals will also follow suit.

Additional source: Johns Hopkins press release
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAR 28, 2020
Cancer
MAR 28, 2020
The Not So Minor Genetic Players in Head and Neck Cancers
Head and neck squamous cell carcinomas (HNSCC) are among the most prevalent cancers among smokers, linked to alcohol con ...
APR 04, 2020
Cancer
APR 04, 2020
Unique Cancer Mutation Hijacks Nearby Signaling Pathway
  In cancer, tyrosine kinase mutations are quite common. MET is one such example that normally binds its native lig ...
APR 13, 2020
Cancer
APR 13, 2020
The Unexpected Role of Mono in Cancer Progression
In the past, the go-to drugs have always been small molecules. These small molecules would interact with the cell and ac ...
APR 19, 2020
Cancer
APR 19, 2020
Discovery of new biomarker detects urological cancer
New hope for the detection of urological cancers has been published in a study in the Journal of Extracellular Vesicles. ...
APR 23, 2020
Cancer
APR 23, 2020
Doctors, watch out for unexpected side effects in small clinical trials
Doctors who have patients in small-sized clinical trials that test new cancer drugs should be on the look-out for unexpe ...
MAY 13, 2020
Cancer
MAY 13, 2020
What role does geography play in childhood cancer?
Research published in the International Journal of Health Geographics aims to explain the role that geography plays in p ...
Loading Comments...